-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Photo: Dr.
Image credit: Mount Sinai Health System
This small but unique study, led by researchers at the Sinai Westville Autism Research and Treatment Center, suggests that low doses of ketamine are generally safe, well tolerated, and effective in treating the clinical symptoms
The ADNP gene affects the formation, development, and function of the brain, and the proteins it produces help control the expression
Alexander Kolevzon, MD, clinical director of the Sever autism Center, said: "We were interested in preclinical evidence that low-dose ketamine may increase levels of the ADNP protein and compensate for its loss in ADNP syndrome, so we designed this study to assess the safety, tolerability and behavioral outcomes
To evaluate the effects of ketamine, the Mount Sinai team used a single dose (0.
The results of the clinical scoring evaluation showed that disease based on the Clinical Global Impression-Improvement scale improved
"We are encouraged by these findings, which provide initial support for ketamine to help reduce the negative effects of this devastating syndrome," said
Ongoing research is using RNA sequencing to measure changes in ADNP expression and other genes, as well as DNA methylation analysis, which has been described as associated
